Hydrogen sulphide: a novel physiological inhibitor of LDL atherogenic modification by HOCl.

@article{Laggner2007HydrogenSA,
  title={Hydrogen sulphide: a novel physiological inhibitor of LDL atherogenic modification by HOCl.},
  author={Hilde Laggner and Markus K. Muellner and Sabine Maria Schreier and Brigitte N Sturm and Marcela Hermann and Markus Exner and Bernhard M. K. Gmeiner and Stylianos Kapiotis},
  journal={Free radical research},
  year={2007},
  volume={41 7},
  pages={741-7}
}
Hypochlorite (HOCl), the product of the activated myeloperoxidase/H(2)O(2)/chloride (MPO/H(2)O(2)/Cl(- )) system is favored as a trigger of LDL modifications, which may play a pivotal role in early atherogenesis. As HOCl has been shown to react with thiol-containing compounds like glutathione and N-acetylcysteine protecting LDL from HOCl modification, we have tested the ability of hydrogen sulfide (H(2)S) - which has recently been identified as an endogenous vasorelaxant - to counteract the… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 43 extracted citations

Similar Papers

Loading similar papers…